Arbutus Biopharma Corporation
ABUS
$5.17
-$0.01-0.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 382.12% | 309.90% | 52.09% | 44.88% | 29.62% |
| Total Depreciation and Amortization | -95.64% | -96.75% | -73.70% | -51.28% | -29.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.07% | -108.77% | -45.94% | 82.75% | 83.48% |
| Change in Net Operating Assets | -1,034.81% | -3,764.05% | -254.29% | -982.66% | -686.52% |
| Cash from Operations | 59.09% | 41.72% | 38.88% | 36.97% | 17.41% |
| Capital Expenditure | -- | -- | -- | 10.42% | 32.81% |
| Sale of Property, Plant, and Equipment | 3,844.44% | -- | -- | -- | -55.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -139.34% | -73.27% | -34.22% | -4.49% | -47.57% |
| Cash from Investing | -138.20% | -71.55% | -32.11% | -4.44% | -47.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 168.16% | -52.04% | -89.00% | -89.88% | -88.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 168.16% | -52.04% | -89.00% | -89.88% | -88.15% |
| Foreign Exchange rate Adjustments | -733.33% | 100.00% | 128.57% | -900.00% | -400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.12% | -121.91% | -282.40% | -165.93% | -171.30% |